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Tamoxifen (TAM) is commonly used to treat estrogen receptor 
(ER)-positive breast cancer. Despite the remarkable benefits, 
resistance to TAM presents a serious therapeutic challenge. 
Since several HOX transcription factors have been proposed as 
strong candidates in the development of resistance to TAM 
therapy in breast cancer, we generated an in vitro model of 
acquired TAM resistance using ER-positive MCF7 breast cancer 
cells (MCF7-TAMR), and analyzed the expression pattern and 
epigenetic states of HOX genes. HOXB cluster genes were 
uniquely up-regulated in MCF7-TAMR cells. Survival analysis 
of in slico data showed the correlation of high expression of 
HOXB genes with poor response to TAM in ER-positive breast 
cancer patients treated with TAM. Gain- and loss-of-function 
experiments showed that the overexpression of multi HOXB 
genes in MCF7 renders cancer cells more resistant to TAM, 
whereas the knockdown restores TAM sensitivity. Furthermore, 
activation of HOXB genes in MCF7-TAMR was associated with 
histone modifications, particularly the gain of H3K9ac. These 
findings imply that the activation of HOXB genes mediate the 
development of TAM resistance, and represent a target for 
development of new strategies to prevent or reverse TAM 
resistance. [BMB Reports 2018; 51(9): 450-455]
INTRODUCTION
Estrogen receptor (ER)-positive breast cancer constitutes almost 
70% of the total number of breast cancer cases (1) and is likely 
to respond favorably to endocrine therapies such as tamoxifen 
(TAM) and aromatase inhibitors (AI). These drugs act by 
competitively binding to ER or by preventing the systemic 
conversion of testosterone to estrogen (2, 3). Even though 
endocrine therapy has been proven relatively safe and has 
significant therapeutic effects, a third of women treated with 
TAM for 5 years will have a relapse of the disease within 15 
years (4). For decades, based on extensive studies investigating 
the molecular mechanisms of resistance to endocrine therapy, 
several important factors, such as ER gene (ESR1) mutations, 
epigenetic aberrations, or crosstalk between ER and growth 
factor signaling, have now come to our attention (5, 6). 
However, the investigation and discovery of novel biomarkers 
are still strongly required to predict responses to TAM 
resistance and develop personalized treatment strategies. 
HOX are highly conserved transcription factors playing 
crucial roles in development, and several HOX genes are 
associated with cancer (7-9). Many previous studies have 
demonstrated abnormal HOX expression in breast cancer 
tissues and culture cells, and furthermore, their roles in 
tumorigenesis and metastasis of breast cancer (10-14). In 
addition, many HOX genes, such as HOXB5, HOXB7, 
HOXB13, HOXC10, HOXC11, and non-coding RNAs in HOX 
clusters are associated with endocrine resistance to breast 
cancer via repression of ER expression or activation of receptor 
tyrosine kinase pathways (15-19). However, the expression 
patterns and the functional characterization of the whole HOX 
cluster genes in TAM-resistant breast cancer cells have not 
been investigated. 
Here, we generated an in vitro TAM resistance model using 
ER-positive MCF7 breast cancer cells (MCF7-TAMR), and 
analyzed the expression patterns of HOX genes as well as their 
epigenetic status. The correlation of HOX gene expression in 
breast cancer patients with survival has been further examined 
using publicly available datasets of human breast cancers. In 
addition, we investigated the functional impact of HOX gene 
expression on TAM sensitization and resistance by conducting 
gain-of-function and loss-of-function experiments. 
RESULTS
HOXB genes are up-regulated in MCF7-TAMR cells
We generated an in vitro TAM-resistant MCF7 cell line 
(MCF7-TAMR) and confirmed the resistance to TAM in a 
concentration-dependent manner (Fig. 1A). MCF7 and MCF7- 
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Fig. 1. Up-regulation of HOXB genes in MCF7-TAMR cells. (A) Cell viability test using MCF7 and MCF7-TAMR cells on day 1 after 
treatment with the indicated concentration of TAM. (B) Cell viability was measured from day 1 to day 4 after treatment with 0 and 12 
M TAM. (C) Real-time PCR analysis of whole HOXB genes, HOXA4, HOXA6, HOXC6, HOXC8, HOXD8, and HOXD9 in MCF7 and 
MCF7-TAMR cells. (A-C) Data are presented as mean ± SEM from at least three independent assays; *P ＜ 0.05; **P ＜ 0.01; ***P ＜
0.001 vs. MCF7, by t-test. (D) Immunocytochemisry of HOXB5 (a-d) and HOXB6 (e-h) in MCF7 and MCF7-TAMR cells.  The images in a, 
c, e, and g were overlaid with DAPI counterstain (×200), and boxed regions were magnified in b, d, f, and h, respectively (×400). (E) 
Western blots of HOXB5 and HOXB6 in MCF7 and MCF7-TAMR cells.
TAMR showed similar cell proliferation rates in normal 
medium, however, MCF7-TAMR cells showed increased 
time-dependent TAM resistance until day 4 (Fig. 1B). To 
investigate the altered HOX gene expression in TAM-resistant 
cells, we analyzed the levels of expression in 39 HOX genes in 
parental MCF7 and -TAMR cells. We found that the entire 
HOXB cluster genes (HOXB2-B13) were significantly up- 
regulated in MCF7-TAMR cells (Fig. 1C). However, only minor 
changes were detected in HOXA, HOXC and HOXD cluster 
genes (Fig. 1C and Supplementary Fig. 1). Representatively, 
the up-regulation of HOXB5 and HOXB6 expression in 
MCF7-TAMR cells was also confirmed at the protein level by 
immunocytochemistry and Western blotting analysis (Fig. 1D 
and E). To investigate whether the up-regulation of any HOXB 
gene is linked to the expression of other nearby HOXB genes, 
we analyzed publicly available datasets related to human 
cancer. We found that each HOXB gene is co-expressed with 
other HOXB genes in human breast cancer patients 
(Supplementary Table 1) suggesting that each HOXB gene 
expression is highly correlated with nearby HOXB genes.
Up-regulation of HOXB mid-cluster genes is associated with 
poor clinical outcome in ER-positive breast cancer 
To assess the degree of survival of breast cancer patients 
depending on their HOXB expression levels, distant 
metastasis-free survival (DMFS) curves were plotted and 
compared using the Kaplan-Meier survival analysis and the 
log-rank test. There was no significant difference in the DMFS 
curves between the HOXB-high and -low groups in all patients 
(Fig. 2A). However, when analyzed only with ER-positive 
patients treated with TAM for therapy, DMFS was significantly 
lower in the HOXB-high groups (Fig. 2B). Among the HOXB 
genes, HOXB5, B6 and B7 genes, in particular, showed a 
significant difference in DMFS between high- and low 
expression groups (Fig. 2C-E). Due to the lack of dataset, the 
impact of HOXB4 expression on breast cancer survival was not 
determined. Multigene prognostic tests also confirmed that the 
high expression of mid-cluster HOXB genes (HOXB5-B7) was 
associated with poor survival of patients with ER-positive 
breast cancer treated with TAM, compared with the anterior 
(HOXB1-B3) or posterior HOXB genes (HOXB8-B13) (Fig. 
2F-H). In contrast, there were no significant differences in 
DMFS curves between the high- and -low expression groups of 
HOXA and HOXC cluster genes in all patients and ER-positive 
patients treated with TAM (Supplementary Fig. 2A-D). In case 
of HOXD cluster genes, the high expression was associated 
with poor prognosis; however, the expression levels were not 
elevated in MCF7-TAMR cells (Supplementary Fig. 1, and 2E 
and F). 
Overexpression of mid-cluster HOXB gene induced TAM 
resistance in MCF7
Previous studies showed that several HOXB genes, such as 
HOXB5, HOXB7, and HOXB13, play a role in TAM resistance 
individually (16, 17, 19). However, there is no evidence to 
suggest whether the overexpression of multiple HOXB genes 
leads to additive or synergistic effects. To explore whether the 
combinatorial overexpression of multiple HOXB genes 
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Fig. 2. Kaplan-Meier analysis of DMFS 
in breast cancer patients based on 
HOXB expression. (A, B) Survival rate 
was compared between groups of high 
and low HOXB expression in (A) all 
patients and in (B) ER-positive patients 
treated with TAM therapy. (C-E) DMFS 
of ER-positive patients who received 
TAM monotherapy were stratified by 
(C) HOXB5, (D) HOXB6, and (E) 
HOXB7 expression level. (F-H) In 
multigene analysis, ER-positive breast 
cancer patients were divided into two 
groups according to the expression 
levels of (F) anterior HOXB 
(HOXB1-B3), (G) middle HOXB 
(HOXB5-B7), and (H) posterior HOXB 
(HOXB8-B13), and analyzed for DMFS.
induces higher TAM resistance compared with that of a single 
HOXB gene, we performed cell proliferation assay in the 
presence of TAM at 24 h post-transfection. Mid-cluster HOXB 
genes (HOXB5, B6 and B7) were used in this experiment 
because of their potential roles in TAM resistance. The 
overexpression of each HOXB gene after transfection was 
confirmed by RT-PCR (Fig. 3A and C). The co-expression of 
HOXB5, HOXB6 and HOXB7 significantly increased the cell 
proliferation rate in the presence of TAM, compared with a 
single HOXB gene (Fig. 3B). The proliferation of MCF7 cells 
transfected with any combination of two HOXB genes (B5/B6, 
B6/B7 and B5/B7) was slightly higher than the values of 
control cells. Furthermore, the overexpression of three 
mid-cluster HOXB genes (HOXB5-B7) led to the highest cell 
proliferation in the presence of TAM (Fig. 3D). Loss-of-function 
studies using HOXB4, instead of HOXB7, as siRNA target 
together with HOXB5 and B6 were performed because the 
up-regulation of HOXB4 in TAMR cells (Fig. 1C) was 
considered much more relevant than the altered expression of 
HOXB7. In a series of knockdown experiments, the reduced 
mRNA expression of HOXB4, B5, and B6 was confirmed (Fig. 
3E, G, and I). Individual sets of MCF7-TAMR cells transfected 
with siRNA for a single gene showed slightly reduced cell 
proliferation in the presence of TAM, however, the effect was 
more pronounced when three HOXB genes were silenced 
simultaneously (Fig. 3F). The same patterns were observed 
when at least two genes (HOXB4/B6 or HOXB5/B6) were 
silenced alone or combined (Fig. 3H and J). 
Activation of HOXB gene expression in MCF7-TAMR cells is 
epigenetically regulated 
The expression of HOX genes is tightly regulated by epigenetic 
mechanisms during normal development and cancer (20, 21). 
Since the HOXB cluster genes were generally upregulated as a 
whole in MCF7-TAMR cells, we expected that different 
epigenetic states can be generated in the HOXB locus during 
the transition to acquired TAM resistance. To test whether 
histone modifications at the HOXB locus serve as markers of 
differential gene expression in MCF7 and MCF7-TAMR cells, 
we performed ChIP analysis. Based on various sources of 
ChIP-Seq data in MCF7 cells deposited into the UCSC 
database, we determined the amplicon sites for the promoter 
region of each HOXB gene (Fig. 4A). ChIP-qPCR results 
revealed that increased H3K9ac at the proximal promoter 
region of each HOXB gene was associated with decreased 
H3K27me3 expression, as the transcript levels increased in 
MCF7-TAMR cells (Fig. 4B).  
DISCUSSION
In this study, we showed that the HOXB cluster genes are 
activated as a whole in TAM-resistant MCF7 breast cancer 
cells. The results of survival analysis indicate that the elevated 
expression of HOXB, especially mid-cluster HOXB, is 
associated with poor survival in patients with ER-positive 
breast cancer who are treated with TAM therapy. Our 
functional studies via overexpression and knockdown 
experiments clearly confirm that the mid-cluster HOXB genes 
contribute to TAM resistance, and the activation of HOXB 
gene expression is mediated by epigenetic mechanisms. 
HOX genes play a diverse role in adult tissues as well as 
during embryogenesis under endocrine control. Therefore, 
endocrine-HOX signaling has important clinical and molecular 
implications for human physiology and pathology (22). In 
human endometrium, HOX genes are dynamically expressed 
under the control of steroid hormones, and the decreased 
HOXA10 expression represents a possible mechanism of 
progesterone resistance in endometriosis (23). Evidence 
increasingly supports the contribution of HOX genes in 
endocrine therapy-resistant breast cancer (15). Although 
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Fig. 3. Effects of mid-cluster HOXB 
genes expression in TAM sensitivity. (A, 
B) MCF7 cells were transfected with 
vector only (MCF7:Vec) and single 
plasmid DNA (MCF7:HOXB5, 
MCF7:HOXB6, MCF7:HOXB7), or 
co-transfected with multiple plasmid 
DNAs simultaneously (MCF7:HOXB5/ 
6/7); (C, D) co-transfected with 2-3 
plasmid DNAs for HOXB5, B6, and B7 
in different combinations (MCF7: 
HOXB5/6, MCF7:HOXB6/7, MCF7: 
HOXB5/7 and MCF7:HOXB5/6/7). (A 
and C): RT-PCR analysis of HOXB5, B6, 
and B7 in each transfectant using 
-ACTIN as an internal control. (B and 
D) All transfectants were treated with 
10 M of TAM and the cell 
proliferation rate was measured by 
CCK-8 assay on day 1. (E, F) MCF7- 
TAMR cells were transfected with 
siRNAs for control, HOXB4, HOXB5, 
HOXB6 (TAMR-siCON, TAMR-siHOX 
B4, TAMR-siHOXB5, TAMR-siHOXB6),
or co-transfected simultaneously (TamR- 
siHOXB4/5/6); (G, H) HOXB4, HOX 
B6; (I, J) HOXB5, HOXB6. (E, G and 
I): Q-PCR analysis for each HOXB 
expression. (F, H, and J): CCK-8 assay 
for cell proliferation rate on day 1. 
Data are presented as mean ± SEM 
from at least three independent assays. 
*P ＜ 0.05, **P ＜ 0.01, ***P ＜
0.001 vs. MCF7: Vec or TAMR-siCON, 
by t-test. #P ＜ 0.05, ##P ＜ 0.01, ###P 
＜ 0.001 vs. MCF7:HOXB5/6/7 or 
TAMR-siHOXB4/5/6 (in F) or TAMR- 
siHOXB5/6 (in J), by t-test.
several HOX genes, such as HOXB7 and HOXB13, in TAM 
resistance have been well characterized (17, 19), cooperative 
and/or synergistic actions of clustered genes in TAM resistance 
have not been reported. Notably, the driving forces, which 
induce dysregulated gene expression in cancer, include gene 
copy number variations, epigenetic regulation, and coordinated 
actions of transcription factors. In this study, we reviewed The 
Cancer Genome Atlas (TCGA) breast cancer data to delineate 
the association between copy number amplification and HOX 
gene expression. We found a lack of positive correlation 
between the expression of HOXB mRNA and copy number in 
breast cancer patient samples (Supplementary Fig. 3), 
suggesting a rare functional relevance of HOXB amplification. 
In support, the copy number assay for each HOXB5 and 
HOXB6 gene locus in cell lines demonstrated a lack of HOX 
amplification in MCF7-TAMR cells compared with MCF7 
(Supplementary Fig. 4). These data strongly exclude the 
possibility that the increase in copy number may have 
contributed to the increased expression. Thus, our proposition 
that the HOXB genes are up-regulated epigenetically in 
MCF7-TAMR cells seems more persuasive. Further, our 
findings support that consecutive HOXB genes mediate TAM 
resistance. 
Nevertheless, additional studies are needed to explain the 
causal mechanism of action. Several HOX proteins sharing a 
high degree of homology are likely to share common 
molecular targets, probably via common signaling pathways. 
Further, non-coding RNAs such as miRNAs and long 
non-coding RNAs (lncRNAs) located in the HOX cluster 
regulate coordinated multi-gene expression during the 
development of TAM resistance. Several studies have shown 
that miRNAs are associated with drug resistance and 
HOXB cluster genes in tamoxifen resistance
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Fig. 4. Histone modifications in MCF7 and MCF7-TAMR cells. (A) 
Screenshot of the HOXB cluster in UCSC genome browser on 
Human (GRCh37/hg19) Assembly (http://genome.ucsc.edu/). Ampli-
cons for each HOXB gene are marked. ChIP-seq data for Pol2 
(GSM822295), H3K4me3 (GSM945269), H3K27me3 (GSM970218)
and H3K27ac (GSM945854) were uploaded as custom tracks in 
the browser. (B) ChIP-qPCR analysis along the HOXB cluster. 
Immunoprecipitated and input DNAs were derived using anti- 
H3K9ac and anti-H3K27me3 antibodies. ChIPed DNAs for IgG 
were used as negative controls. Primers for gene desert regions 
were used as negative controls (gene desert #1: Chr 16: 
62,732,615-62,732,729; gene desert #2: Chr 20: 56,403,369- 
56,403,521). Data are expressed as the percentage of input, after 
normalization with IgG; *P ＜ 0.05, **P ＜ 0.01.
prediction of outcome and therapeutic response in breast 
cancer (24, 25). MiR-196a and miR-10a, which are located in 
the HOXB loci, in particular, mediate endocrine resistance (15, 
26). Although the potential cis- or trans-actions of these 
non-coding RNAs in multi-gene regulation, particularly in 
breast cancer cells resistant to TAM, remain to be characterized, 
this possibility must be taken into consideration. 
Meanwhile, several studies have reported that epigenetic 
alterations are associated with drug resistance in breast cancer 
(27, 28). In this study, we showed the up-regulation of HOXB 
gene expression in TAM-resistant breast cancer cells, with 
accompanying changes in histone modification along the 
whole cluster. Consistent with these findings, a previous study 
of Barrett’s esophagus (BE) showed that the activation of three 
consecutive mid-cluster HOXB genes (HOXB5-B7) is epi-
genetically correlated with H3K27me and AcH3 levels and 
chromatin compaction (29). Several human diseases including 
cancer are associated with altered high-order chromatin 
structure (30). Particularly, HoxBlinc (hoxb locus-associated 
long intergenic non-coding RNA) located between hoxb4 and 
-b5, has been known to regulate hoxb gene transcription by 
modulating local chromatin alterations during murine 
embryonic stem cell differentiation (31). Considering the role 
of HoxBlinc RNA during embryogenesis in recruiting Set1/MLL 
complexes containing methyltransferase activity for H3K4 and 
its effect on 3D chromatin architecture, it is reasonable to 
expect that a large variety of lncRNAs modulate chromatin 
structure and gene expression in cancer cells. 
In conclusion, we have shown the simultaneous activation 
of HOXB genes in TAM-resistant breast cancer cells and 
demonstrated the functional roles of mid-cluster HOXB genes 
in sensitizing and desensitizing TAM effect. These findings not 
only provide insight into the cumulative effect of HOXB gene 
expression in TAM resistance, but may also facilitate the 
development of new therapeutic approaches to re-sensitize 
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